GLAUKOS Corp — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Glaukos (market cap ~$5.9B) presented an August 2026 investor presentation outlining its pipeline and commercial strategy across three therapeutic areas: interventional glaucoma (iDose TR approved Jan 2026 for re-administration; iDose TRIO in Phase 3b; iDose TREX in Phase 2b/3), keratoconus (Epioxa FDA-approved March 2026; iLink 3rd gen in Phase 2), and emerging platforms (iLution for blepharitis in Phase 2; Retina XR biodegradable implant in Phase 2a). Financial snapshot: 2025 net sales $507M (30% YoY growth from 2024), guidance for 2026 midpoint $690M, gross margin 85%, cash $289M with no debt as of 6/30/2026.
Why this rating
Investor presentation disclosing known pipeline milestones and commercial progress. No material new financing, M&A, regulatory action, or guidance miss. Routine disclosure of existing product approvals and trial status.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.